Inflammatory biomarkers for persistent fatigue in breast cancer survivors

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2759-2766

  Collado Hidalgo, Alicia ^a   Bower, Julienne E ^a,b   Ganz, Patricia A ^b   Cole, Steve W ^a,b   Irwin, Michael R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; IMMUNOLOGIC FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER SURVIVOR; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONOCYTE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FATIGUE; FEMALE; HUMANS; INFLAMMATION; LYMPHOCYTE COUNT; MIDDLE AGED; SURVIVORS;

EID: 33646733403     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2398     Document Type: Article

References (50)

1. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002;360:1131-5.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743-53.
5. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 2002;38:27-43.
6. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49.
7. Dantzer R, Bluthe RM, Laye S, Bret-Dibat JL, Parnet P, Kelley KW. Cytokines and sickness behavior. Ann N Y Acad Sci 1998;840:586-90.
8. Dantzer R, Bluthe RM, Gheusi G, et al. Molecular basis of sickness behavior. Ann N Y Acad Sci 1998;856:132-8.
9. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003;17 Suppl 1:S112-8.
10. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003;97:2919-25.
11. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:7-24.
12. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-9.
13. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-7.
14. Gaab J, Rohleder N, Heitz V, et al. Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005;30:188-98.
15. Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol 2005;69:85-96.
16. Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993;8:196-200.
17. Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001;51:691-8.
18. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102.
19. Wratten C, Kilmurray J, Nash S, et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 2004;59:160-7.
20. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-11.
21. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 2003;95:1165-8.
22. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
23. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1-8.
24. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994;15:479-83.
25. Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, Sanchez-Madrid F. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988;168:1621-37.
26. Kallen KJ. The role of trans-signalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002;1592:323-43.
27. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004;202:250-65.
28. Satoh M, Shimoda Y, Maesawa C, et al. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 2005;Jul 25 [Epub ahead of print].
29. Herskind C, Bamberg M, Rodemann HP. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 1998;174 Suppl 3:12-5.
30. +) Tcells and decrease of "naive" (CD4-45R) T lymphocytes. Eur J Cancer 1992;28A:1729-34.
31. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90:3789-98.
32. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 1998;7:301-10.
33. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 2005;67:277-80.
34. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005;30:92-100.
35. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-27.
36. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-7.
37. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005;67:187-94.
38. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006;20:169-74.
39. Dillon W, Goldstein M. Multivariate analysis: methods and applications. New York: John Wiley & Sons; 1984.
40. Hastie T, Tibshirani R, Firedman J. The elements of statistical learning: data mining, interference, and prediction. New York: Springer; 2001.
41. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 trans-signaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53.
42. Rose-John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003;50:603-11.
43. Jameel JK, Rao VS, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast 2004;13:452-60.
44. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation of human Vα24(+)Vβ11 (+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004;91:1880-6.
45. Glaser R, Padgett DA, Litsky ML, et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav Immun 2005;19:91-103.
46. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002;2:311-5.
47. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999;19:1427-32.
48. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005;175:3463-8.
49. + cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun 2005;19:389-97.
50. Boehmer ED, Goral J, Faunce DE, Kovacs EJ. Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J Leukoc Biol 2004;75:342-9.